Declining efficacy of artemisinin combination therapy against P. falciparum malaria on the Thai-Myanmar border (2003-2013): The role of parasite genetic factors.

<h4>Background</h4> <p>Deployment of mefloquine–artesunate (MAS3) on the Thailand–Myanmar border has led to a sustained reduction in falciparum malaria, although antimalarial efficacy has declined substantially in recent years. The role of Plasmodium falciparum K13 mutations (a ma...

पूर्ण विवरण

ग्रंथसूची विवरण
मुख्य लेखकों: Phyo, A, Ashley, E, Anderson, T, Bozdech, Z, Carrara, V, Sriprawat, K, Nair, S, White, M, Dziekan, J, Ling, C, Proux, S, Konghahong, K, Jeeyapant, A, Woodrow, C, Imwong, M, McGready, R, Lwin, K, Day, N, White, N, Nosten, F
स्वरूप: Journal article
भाषा:English
प्रकाशित: Oxford University Press 2016
_version_ 1826291918441545728
author Phyo, A
Ashley, E
Anderson, T
Bozdech, Z
Carrara, V
Sriprawat, K
Nair, S
White, M
Dziekan, J
Ling, C
Proux, S
Konghahong, K
Jeeyapant, A
Woodrow, C
Imwong, M
McGready, R
Lwin, K
Day, N
White, N
Nosten, F
author_facet Phyo, A
Ashley, E
Anderson, T
Bozdech, Z
Carrara, V
Sriprawat, K
Nair, S
White, M
Dziekan, J
Ling, C
Proux, S
Konghahong, K
Jeeyapant, A
Woodrow, C
Imwong, M
McGready, R
Lwin, K
Day, N
White, N
Nosten, F
author_sort Phyo, A
collection OXFORD
description <h4>Background</h4> <p>Deployment of mefloquine–artesunate (MAS3) on the Thailand–Myanmar border has led to a sustained reduction in falciparum malaria, although antimalarial efficacy has declined substantially in recent years. The role of Plasmodium falciparum K13 mutations (a marker of artemisinin resistance) in reducing treatment efficacy remains controversial.</p> <h4>Methods</h4> <p>Between 2003 and 2013, we studied the efficacy of MAS3 in 1005 patients with uncomplicated P. falciparum malaria in relation to molecular markers of resistance.</p> <h4>Results</h4> <p>Polymerase chain reaction (PCR)–adjusted cure rates declined from 100% in 2003 to 81.1% in 2013 as the proportions of isolates with multiple Pfmdr1 copies doubled from 32.4% to 64.7% and those with K13 mutations increased from 6.7% to 83.4%. K13 mutations conferring moderate artemisinin resistance (notably E252Q) predominated initially but were later overtaken by propeller mutations associated with slower parasite clearance (notably C580Y). Those infected with both multiple Pfmdr1 copy number and a K13 propeller mutation were 14 times more likely to fail treatment. The PCR-adjusted cure rate was 57.8% (95% confidence interval [CI], 45.4, 68.3) compared with 97.8% (95% CI, 93.3, 99.3) in patients with K13 wild type and Pfmdr1 single copy. K13 propeller mutation alone was a strong risk factor for recrudescence (P = .009). The combined population attributable fraction of recrudescence associated with K13 mutation and Pfmdr1 amplification was 82%.</p> <h4>Conclusions</h4> <p>The increasing prevalence of K13 mutations was the decisive factor for the recent and rapid decline in efficacy of artemisinin-based combination (MAS3) on the Thailand–Myanmar border.</p>
first_indexed 2024-03-07T03:06:43Z
format Journal article
id oxford-uuid:b2cabe99-d401-4aa3-935f-05f3fcf7d90b
institution University of Oxford
language English
last_indexed 2024-03-07T03:06:43Z
publishDate 2016
publisher Oxford University Press
record_format dspace
spelling oxford-uuid:b2cabe99-d401-4aa3-935f-05f3fcf7d90b2022-03-27T04:14:19ZDeclining efficacy of artemisinin combination therapy against P. falciparum malaria on the Thai-Myanmar border (2003-2013): The role of parasite genetic factors.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:b2cabe99-d401-4aa3-935f-05f3fcf7d90bEnglishSymplectic Elements at OxfordOxford University Press2016Phyo, AAshley, EAnderson, TBozdech, ZCarrara, VSriprawat, KNair, SWhite, MDziekan, JLing, CProux, SKonghahong, KJeeyapant, AWoodrow, CImwong, MMcGready, RLwin, KDay, NWhite, NNosten, F <h4>Background</h4> <p>Deployment of mefloquine–artesunate (MAS3) on the Thailand–Myanmar border has led to a sustained reduction in falciparum malaria, although antimalarial efficacy has declined substantially in recent years. The role of Plasmodium falciparum K13 mutations (a marker of artemisinin resistance) in reducing treatment efficacy remains controversial.</p> <h4>Methods</h4> <p>Between 2003 and 2013, we studied the efficacy of MAS3 in 1005 patients with uncomplicated P. falciparum malaria in relation to molecular markers of resistance.</p> <h4>Results</h4> <p>Polymerase chain reaction (PCR)–adjusted cure rates declined from 100% in 2003 to 81.1% in 2013 as the proportions of isolates with multiple Pfmdr1 copies doubled from 32.4% to 64.7% and those with K13 mutations increased from 6.7% to 83.4%. K13 mutations conferring moderate artemisinin resistance (notably E252Q) predominated initially but were later overtaken by propeller mutations associated with slower parasite clearance (notably C580Y). Those infected with both multiple Pfmdr1 copy number and a K13 propeller mutation were 14 times more likely to fail treatment. The PCR-adjusted cure rate was 57.8% (95% confidence interval [CI], 45.4, 68.3) compared with 97.8% (95% CI, 93.3, 99.3) in patients with K13 wild type and Pfmdr1 single copy. K13 propeller mutation alone was a strong risk factor for recrudescence (P = .009). The combined population attributable fraction of recrudescence associated with K13 mutation and Pfmdr1 amplification was 82%.</p> <h4>Conclusions</h4> <p>The increasing prevalence of K13 mutations was the decisive factor for the recent and rapid decline in efficacy of artemisinin-based combination (MAS3) on the Thailand–Myanmar border.</p>
spellingShingle Phyo, A
Ashley, E
Anderson, T
Bozdech, Z
Carrara, V
Sriprawat, K
Nair, S
White, M
Dziekan, J
Ling, C
Proux, S
Konghahong, K
Jeeyapant, A
Woodrow, C
Imwong, M
McGready, R
Lwin, K
Day, N
White, N
Nosten, F
Declining efficacy of artemisinin combination therapy against P. falciparum malaria on the Thai-Myanmar border (2003-2013): The role of parasite genetic factors.
title Declining efficacy of artemisinin combination therapy against P. falciparum malaria on the Thai-Myanmar border (2003-2013): The role of parasite genetic factors.
title_full Declining efficacy of artemisinin combination therapy against P. falciparum malaria on the Thai-Myanmar border (2003-2013): The role of parasite genetic factors.
title_fullStr Declining efficacy of artemisinin combination therapy against P. falciparum malaria on the Thai-Myanmar border (2003-2013): The role of parasite genetic factors.
title_full_unstemmed Declining efficacy of artemisinin combination therapy against P. falciparum malaria on the Thai-Myanmar border (2003-2013): The role of parasite genetic factors.
title_short Declining efficacy of artemisinin combination therapy against P. falciparum malaria on the Thai-Myanmar border (2003-2013): The role of parasite genetic factors.
title_sort declining efficacy of artemisinin combination therapy against p falciparum malaria on the thai myanmar border 2003 2013 the role of parasite genetic factors
work_keys_str_mv AT phyoa decliningefficacyofartemisinincombinationtherapyagainstpfalciparummalariaonthethaimyanmarborder20032013theroleofparasitegeneticfactors
AT ashleye decliningefficacyofartemisinincombinationtherapyagainstpfalciparummalariaonthethaimyanmarborder20032013theroleofparasitegeneticfactors
AT andersont decliningefficacyofartemisinincombinationtherapyagainstpfalciparummalariaonthethaimyanmarborder20032013theroleofparasitegeneticfactors
AT bozdechz decliningefficacyofartemisinincombinationtherapyagainstpfalciparummalariaonthethaimyanmarborder20032013theroleofparasitegeneticfactors
AT carrarav decliningefficacyofartemisinincombinationtherapyagainstpfalciparummalariaonthethaimyanmarborder20032013theroleofparasitegeneticfactors
AT sriprawatk decliningefficacyofartemisinincombinationtherapyagainstpfalciparummalariaonthethaimyanmarborder20032013theroleofparasitegeneticfactors
AT nairs decliningefficacyofartemisinincombinationtherapyagainstpfalciparummalariaonthethaimyanmarborder20032013theroleofparasitegeneticfactors
AT whitem decliningefficacyofartemisinincombinationtherapyagainstpfalciparummalariaonthethaimyanmarborder20032013theroleofparasitegeneticfactors
AT dziekanj decliningefficacyofartemisinincombinationtherapyagainstpfalciparummalariaonthethaimyanmarborder20032013theroleofparasitegeneticfactors
AT lingc decliningefficacyofartemisinincombinationtherapyagainstpfalciparummalariaonthethaimyanmarborder20032013theroleofparasitegeneticfactors
AT prouxs decliningefficacyofartemisinincombinationtherapyagainstpfalciparummalariaonthethaimyanmarborder20032013theroleofparasitegeneticfactors
AT konghahongk decliningefficacyofartemisinincombinationtherapyagainstpfalciparummalariaonthethaimyanmarborder20032013theroleofparasitegeneticfactors
AT jeeyapanta decliningefficacyofartemisinincombinationtherapyagainstpfalciparummalariaonthethaimyanmarborder20032013theroleofparasitegeneticfactors
AT woodrowc decliningefficacyofartemisinincombinationtherapyagainstpfalciparummalariaonthethaimyanmarborder20032013theroleofparasitegeneticfactors
AT imwongm decliningefficacyofartemisinincombinationtherapyagainstpfalciparummalariaonthethaimyanmarborder20032013theroleofparasitegeneticfactors
AT mcgreadyr decliningefficacyofartemisinincombinationtherapyagainstpfalciparummalariaonthethaimyanmarborder20032013theroleofparasitegeneticfactors
AT lwink decliningefficacyofartemisinincombinationtherapyagainstpfalciparummalariaonthethaimyanmarborder20032013theroleofparasitegeneticfactors
AT dayn decliningefficacyofartemisinincombinationtherapyagainstpfalciparummalariaonthethaimyanmarborder20032013theroleofparasitegeneticfactors
AT whiten decliningefficacyofartemisinincombinationtherapyagainstpfalciparummalariaonthethaimyanmarborder20032013theroleofparasitegeneticfactors
AT nostenf decliningefficacyofartemisinincombinationtherapyagainstpfalciparummalariaonthethaimyanmarborder20032013theroleofparasitegeneticfactors